These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14712317)

  • 1. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.
    Mincheff M; Zoubak S; Altankova I; Tchakarov S; Makogonenko Y; Botev C; Ignatova I; Dimitrov R; Madarzhieva K; Hammett M; Pomakov Y; Meryman H; Lissitchkov T
    Cancer Gene Ther; 2003 Dec; 10(12):907-17. PubMed ID: 14712317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.
    Mincheff M; Zoubak S; Altankova I; Tchakarov S; Pogribnyy P; Makogonenko Y; Botev C; Meryman HT
    Cancer Gene Ther; 2005 Feb; 12(2):185-97. PubMed ID: 15375382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.
    Smith SG; Patel PM; Porte J; Selby PJ; Jackson AM
    Clin Cancer Res; 2001 Dec; 7(12):4253-61. PubMed ID: 11751527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
    Kuang Y; Weng X; Liu X; Zhu H; Chen Z; Jiang B; Chen H
    Cancer Lett; 2010 Jul; 293(2):254-62. PubMed ID: 20149524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals.
    Mincheff M; Zoubak S; Makogonenko Y
    Cancer Gene Ther; 2006 Apr; 13(4):436-44. PubMed ID: 16276349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
    Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
    Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
    Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
    Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.
    Youlin K; Li Z; Xin G; Mingchao X; Xiuheng L; Xiaodong W
    Hum Vaccin Immunother; 2013 Apr; 9(4):766-72. PubMed ID: 23295983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
    Meng FD; Wang S; Jiang YH; Sui CG
    Mol Med Rep; 2016 Mar; 13(3):2124-34. PubMed ID: 26783185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells.
    Wang K; Gao X; Pang J; Liu X; Cai Y; Zhang Y; Zhou J; Zhan H
    Urol Oncol; 2009; 27(1):26-32. PubMed ID: 18367124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
    Kobayashi H; Omiya R; Sodey B; Yanai M; Oikawa K; Sato K; Kimura S; Senju S; Nishimura Y; Tateno M; Celis E
    Clin Cancer Res; 2003 Nov; 9(14):5386-93. PubMed ID: 14614024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
    Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
    Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
    Lu J; Celis E
    Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.